The results showed that HSD17B13 expression was no different between HBV infection and HBV un-infection in neither NASH nor in cirrhotic liver tissues (Figure 1C), though its expression was significantly up-regulated when compared to normal liver tissues (Figure 1C), suggesting that HSD17B13 expression is higher in the livers of patients with NAFLD, regardless of etiology. Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.